Want to see A full AI Analyst Report?
Top Page
Agilent
(NYSE:A)
Select Model
Select Model
Rating:71Outperform
Price Target:
$150.00
▲(8.25% Upside)
Action:Reiterated
Date:05/29/26
The score is driven primarily by solid underlying financial performance (profitability/returns and free cash flow) and a constructive earnings update with raised FY26 guidance and margin expansion. Offsetting this are a fairly expensive valuation (P/E ~27, low yield) and mixed technical momentum (negative MACD despite price being above key moving averages).
Positive Factors
Recurring consumables & services
Agilent’s mix of capital equipment plus recurring consumables, reagents, software and services builds durable, high-frequency revenue from an expanding installed base. This recurring stream improves revenue visibility, supports gross-margin stability and cushions cyclicality tied to one-time instrument sales over the next 2–6 months.
Negative Factors
China end-market exposure
Meaningful exposure to China leaves growth vulnerable to funding timing, policy shifts and local demand cycles. Prolonged weakness or delayed stimulus can materially depress instrument orders and consumables consumption, creating persistent headwinds to organic growth and near-term guidance conversion.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring consumables & services
Agilent’s mix of capital equipment plus recurring consumables, reagents, software and services builds durable, high-frequency revenue from an expanding installed base. This recurring stream improves revenue visibility, supports gross-margin stability and cushions cyclicality tied to one-time instrument sales over the next 2–6 months.
Read all positive factors
Agilent Key Performance Indicators (KPIs)
Any
Revenue by Geography
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Data provided by:
The Fly
The FlyAgilent (A) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$39.63B
Dividend Yield0.59%
Average Volume (3M)2.20M
Price to Earnings (P/E)28.2
Beta (1Y)0.90
Revenue Growth9.11%
EPS Growth22.77%
CountryUS
Employees18,100
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)4.99
Shares Outstanding282,431,950
10 Day Avg. Volume2,342,360
30 Day Avg. Volume2,199,263
Financial Highlights & Ratios
PEG Ratio9.44
Price to Book (P/B)6.14
Price to Sales (P/S)5.96
P/FCF Ratio35.95
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$155.13Price Target Upside11.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
EPS Forecast (FY)6.06
Revenue Forecast (FY)$7.45B
Agilent Business Overview & Revenue Model
Company Description
Agilent Technologies, Inc. (A) is a life sciences, diagnostics, and applied chemical analysis company that provides instruments, software, consumables, and services used in laboratories worldwide. The company serves pharmaceutical and biotechnolog...
How the Company Makes Money
Agilent makes money primarily by selling laboratory solutions that combine capital equipment (instruments) with recurring purchases (consumables) and ongoing support (services and software). A significant portion of revenue comes from selling anal...
Agilent Earnings Call Summary
Earnings Call Date:May 27, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Aug 26, 2026
Earnings Call Sentiment Positive
The call presented a strong operational and financial performance: revenue, margins, and EPS all beat expectations, management raised full‑year guidance, and multiple indicators (instrument orders, segment outperformance, pricing, supply chain resilience and product innovation) point to durable momentum. Near-term challenges include China softness, food and academia/government weakness, and inflationary/geopolitical cost pressures that add uncertainty. On balance the positive operational wins and upgraded guidance outweigh the cited headwinds.Positive Updates
Revenue and Growth Beat
Q2 revenue of $1.83B, core (organic constant currency) growth of 6.3% YoY (reported +10% with a 3.7% currency tailwind), beating the high end of guidance by 80 bps.
Negative Updates
China Softness
China revenue declined 9% in Q2 (first half roughly flat); softness driven by Lunar New Year timing and delayed government funding; company expects revenue impact to be weighted into next fiscal year stimulus timing.
Read all updates
Q2-2026 Updates
Positive
Negative
Revenue and Growth Beat
Q2 revenue of $1.83B, core (organic constant currency) growth of 6.3% YoY (reported +10% with a 3.7% currency tailwind), beating the high end of guidance by 80 bps.
Read all positive updates
Company Guidance
Agilent updated FY26 guidance to reported revenue of $7.39–$7.49 billion (core/organic constant‑currency growth 4.5%–6.0%, midpoint +30 bps vs. prior) with a ~1.8% currency tailwind, raised full‑year non‑GAAP EPS to $6.00–$6.10 (up $0.08 at the midpoint; ~7%–9% EPS growth) and increased the operating‑margin expansion target to ~85 bps at the midpoint; Q3 revenue is guided to $1.83–$1.85 billion (core growth ~4.4%–5.9%) with Q3 EPS $1.48–$1.50 (8%–9% growth) and an estimated Q3 currency tailwind of ~0.6%; the company assumes 283 million diluted shares, a 14.5% tax rate, ~$31 million other income, FY capex of ~ $450 million (down $50M), operating cash flow of $1.2–$1.7 billion, and maintained net leverage around 0.7x—guidance excludes Biocare and any tariff‑refund upside and reflects expected continued benefit from Ignite (including the ~200 bps of pricing realized in Q2) to help absorb inflationary and geopolitical cost pressures.Agilent Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
74
Positive
Cash Flow
71
Positive
| Breakdown | TTM | Oct 2025 | Oct 2024 | Oct 2023 | Oct 2022 | Oct 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.23B | 6.95B | 6.51B | 6.83B | 6.85B | 6.32B |
| Gross Profit | 3.83B | 3.64B | 3.54B | 3.46B | 3.72B | 3.41B |
| EBITDA | 1.96B | 1.83B | 1.87B | 1.70B | 1.91B | 1.76B |
| Net Income | 1.41B | 1.30B | 1.29B | 1.24B | 1.25B | 1.21B |
Balance Sheet | ||||||
| Total Assets | 13.06B | 12.73B | 11.85B | 10.76B | 10.53B | 10.71B |
| Cash, Cash Equivalents and Short-Term Investments | 1.81B | 1.79B | 1.33B | 1.59B | 1.05B | 1.57B |
| Total Debt | 3.35B | 3.35B | 3.57B | 2.73B | 2.77B | 2.73B |
| Total Liabilities | 5.94B | 5.99B | 5.95B | 4.92B | 5.23B | 5.32B |
| Stockholders Equity | 7.12B | 6.74B | 5.90B | 5.84B | 5.30B | 5.39B |
Cash Flow | ||||||
| Free Cash Flow | 1.26B | 1.15B | 1.37B | 1.47B | 1.02B | 1.30B |
| Operating Cash Flow | 1.45B | 1.56B | 1.75B | 1.77B | 1.31B | 1.49B |
| Investing Cash Flow | -356.00M | -394.00M | -1.26B | -310.00M | -338.00M | -749.00M |
| Financing Cash Flow | -785.00M | -715.00M | -752.00M | -930.00M | -1.37B | -696.00M |
Agilent Technical Analysis
Positive
138.57
Price Trends
130.45
Positive
122.54
Positive
130.52
Positive
Market Momentum
1.98
Negative
61.41
Neutral
79.35
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For A, the sentiment is Positive. The current price of 138.57 is above the 20-day moving average (MA) of 134.40, above the 50-day MA of 130.45, and above the 200-day MA of 130.52, indicating a bullish trend. The MACD of 1.98 indicates Negative momentum. The RSI at 61.41 is Neutral, neither overbought nor oversold. The STOCH value of 79.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for A.
Agilent Risk Analysis
Agilent disclosed 35 risk factors in its most recent earnings report. Agilent reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Agilent Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $214.22B | 30.96 | 13.35% | 0.32% | 7.23% | 7.47% | |
74 Outperform | $40.75B | 29.93 | 21.95% | ― | 8.22% | 16.68% | |
71 Outperform | $39.63B | 28.18 | 20.84% | 0.59% | 9.11% | 22.77% | |
69 Neutral | $37.26B | 48.72 | 8.04% | ― | 26.39% | -28.79% | |
68 Neutral | $138.13B | 35.24 | 7.66% | 0.75% | 4.56% | 19.34% | |
64 Neutral | $28.05B | 32.48 | -610.32% | ― | 6.78% | 6.19% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
A
Agilent
138.71
24.81
21.79%
DHR
Danaher
196.17
0.45
0.23%
MTD
Mettler-Toledo
1,380.61
146.93
11.91%
TMO
Thermo Fisher
576.77
110.79
23.78%
WAT
Waters
380.30
91.54
31.70%
IQV
IQVIA Holdings
237.79
51.93
27.94%
Agilent Corporate Events
Private Placements and FinancingRegulatory Filings and Compliance
Agilent Completes $600 Million Senior Notes Offering
Neutral
Jun 25, 2026
On June 25, 2026, Agilent Technologies closed a $600 million private offering of 4.900% senior unsecured notes due January 15, 2032, sold to qualified institutional buyers under Rule 144A and to non-U.S. investors under Regulation S. The notes, pr...
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresRegulatory Filings and Compliance
Agilent Appoints New Chief Accounting Officer Amid Growth
Positive
May 27, 2026
On May 20, 2026, Agilent appointed Tim Downs as vice president and chief accounting officer, effective after the filing of its April 30, 2026 Form 10-Q, succeeding retiring principal accounting officer Rodney Gonsalves, who will stay on in a trans...
Business Operations and StrategyExecutive/Board Changes
Agilent Names New Chief Legal Officer Amid Leadership Transition
Positive
May 4, 2026
On May 4, 2026, Agilent Technologies Inc. appointed Michael Buckner as chief legal officer, succeeding Bret DiMarco, who resigned from his roles as senior vice president, chief legal officer, and secretary on the same date under a previously discl...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.